Publications by authors named "Misery Laurent"

Article Synopsis
  • Atopic dermatitis (AD) significantly affects patients' quality of life, causing itching, skin pain, and sleep disturbances; ruxolitinib cream has shown effectiveness in treating these symptoms in adults and adolescents through two phase III clinical trials.
  • In the TRuE-AD studies, patients applied different strengths of ruxolitinib cream or a vehicle cream, with results indicating that those using ruxolitinib experienced quick relief from symptoms like skin pain and sleep issues within hours or weeks of application.
  • Analysis of patient-reported outcomes revealed notable improvements in overall quality of life and symptom burden after two weeks of using ruxolitinib cream compared to the vehicle, with sustained benefits observed throughout the study periods.
View Article and Find Full Text PDF
Article Synopsis
  • Hidradenitis suppurativa (HS) can greatly impact patients' quality of life due to its association with psychological issues like anxiety and depression, often intensified by stigmatization related to physical appearance.
  • A study involving 135 HS patients from 22 dermatology clinics in Europe found significant levels of perceived stigmatization, which correlated with disease duration, itchiness, and depression symptoms.
  • The research emphasizes the need for comprehensive management of HS, including addressing psychological well-being and access to mental health support for better patient outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • * The article highlights the significance of incorporating mind-body therapies (MBT) in treating AD, including techniques like meditation, cognitive behavioral therapy, and mindfulness.
  • * Although research is limited, a holistic approach combining MBT and traditional treatments may enhance symptom management and psychological health, especially by breaking the itch-scratch cycle.
View Article and Find Full Text PDF

Chronic pruritus (CP) is defined as an unpleasant sensation causing a desire to scratch and lasting > 6 weeks. It has a multifactorial etiology but is more frequently associated with chronic inflammatory dermatoses and systemic disorders. Psychogenic pruritus and neurological disorders are other less common etiologies, while, in some patients, it is idiopathic.

View Article and Find Full Text PDF
Article Synopsis
  • - A global study conducted from January to April 2023 assessed pruritus (itching) prevalence among 50,552 individuals across 20 countries, revealing an overall prevalence of 39.8%.
  • - The study found that older adults (65+) had the highest prevalence at 43.3%, with women experiencing pruritus more frequently (40.7%) than men (38.9%).
  • - Geographic differences showed higher pruritus rates in Africa (45.7%) compared to North America (41.2%) and lower rates in Europe (35.9%) and Australia (38.4%), with no notable ethnic differences in prevalence.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores the effectiveness of one-on-one, nurse-led therapeutic patient education (TPE) for children with moderate-to-severe atopic dermatitis (AD), pitting it against standard care alone.
  • A total of 176 children participated, but by week 24, there was no significant difference in disease control (measured by the SCORAD index) between the two groups.
  • The only notable improvement from the TPE was a reduction in fear of using topical steroids, although the intervention group displayed consistently lower disease severity throughout the study.
View Article and Find Full Text PDF

Chronic kidney disease-associated pruritus (CKD-aP) is a disabling symptom which is frequent and often underestimated. Pa-MRC has a negative impact on quality of life, and is frequently accompanied by sleep disorders and depression. The approval of difelikefalin – a kappa opioid receptor agonist – in this indication requires updated recommendations.

View Article and Find Full Text PDF

The effects of air pollution on health are gaining increasing research interest with limited data on skin alterations available. It was suggested that air pollution is a trigger factor for sensitive skin (SS). However, this data was based on surveys with a lack of experimental data.

View Article and Find Full Text PDF
Article Synopsis
  • The Ritux 3 trial showed that rituximab is effective and safe as a first-line treatment for pemphigus, although long-term follow-up data was previously lacking.!* -
  • This 7-year follow-up study evaluated the long-term outcomes for patients treated with rituximab alongside prednisone versus those treated with prednisone alone, focusing on disease-free survival and relapse rates.!* -
  • Results indicated that 93% of patients in the rituximab group achieved complete remission without corticosteroids, showing significantly higher disease-free survival and lower relapse rates compared to the prednisone-only group.!*
View Article and Find Full Text PDF

Introduction: Several classifications of psychodermatology disorders have been proposed, with most of them based on two to four main disorder category groups. However, there is, to date, no classification that has resulted from a consensus established by psychodermatology experts. The DSM-5-TR (Diagnostic and statistical manual of mental disorders (5th ed.

View Article and Find Full Text PDF

Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden.

Objectives: The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.

Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]).

View Article and Find Full Text PDF

Background: The causes of pruritus are multiple and commonly classified into six different categories: dermatological, systemic, neuropathic, psychogenic, mixed and idiopathic. In clinical practice, psychogenic and neurogenic mechanisms tend to be separated in the etiological diagnosis of neuropathic or psychogenic disorders; nevertheless, studies investigating the respective psychogenic and neurogenic components are lacking.

Objective: The main objective of this work was to highlight the differences and potential common characteristics between psychogenic pruritus and neuropathic pruritus.

View Article and Find Full Text PDF

Background: Baricitinib treatment in adults with moderate-to-severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids (TCS). As EASI clinical signs differ in time course and associated antecedents, the effects of baricitinib on each individual clinical sign are of interest.

Objectives: In this post hoc analysis, we aimed to investigate the effects of baricitinib on individual EASI subscores, namely excoriation, oedema/papulation, erythema and lichenification, in both monotherapy and TCS combination therapy trials.

View Article and Find Full Text PDF

Background: Chronic kidney disease-associated pruritus (CKD-aP) is common in hemodialysis patients and severely impairs their quality of life, but the practices of nephrologists remain poorly known.

Methods: The objective of this on-line survey was to describe the management of CKD-aP in French nephrologists affiliated with the French-speaking Society of Nephrology, Dialysis and Transplantation (SFNDT) and involved in hemodialysis.

Results: In total, 122 questionnaires were completed and 100 were usable.

View Article and Find Full Text PDF
Article Synopsis
  • Prurigo nodularis is a chronic skin disease causing intense itching, and nemolizumab, an IL-31 receptor antagonist, targets its underlying mechanisms.* -
  • In a phase 3 trial, 274 adults with moderate-to-severe prurigo nodularis were given nemolizumab or a placebo for 16 weeks, showing significant improvements in itch and overall skin condition.* -
  • Results revealed that 56.3% of the nemolizumab group reported reduced itching compared to 20.9% in the placebo group, with similar trends observed for other secondary outcomes, demonstrating its efficacy (P<0.001).*
View Article and Find Full Text PDF

Background: This review summarizes uses and new applications for dermatological research of in vitro culture models of human skin explants (HSEs). In the last decade, many innovations have appeared in the literature and an exponential number of studies have been recorded in various fields of application such as process culture engineering, stem cell extractions methodology, or cell-to-cell interaction studies under physiological and pathological conditions, wound-healing, and inflammation. Most studies also concerned pharmacology, cosmetology, and photobiology.

View Article and Find Full Text PDF

Psychodermatology is a subspecialty of dermatology that is of increasing interest to dermatologists and patients. The case for the provision of at least regional psychodermatology services across Europe is robust. Psychodermatology services have been shown to have better, quicker and more cost-efficient clinical outcomes for patients with psychodermatological conditions.

View Article and Find Full Text PDF